Posted on 25/06/2009 in Pharmaceutical Company Product News Takeda looks forward to developing Tak-536, it has said.
Phase III clinical trials of the investigational compound ? which is a novel angiotensin receptor blocker (ARB) ? have begun.
By inhibiting the action of the vasopressor hormone angiotensin II, it is able to lower blood pressure and is being investigated.
During the examinations, the compound is expected to show stronger anti-hypertensive action compared to Takeda's marketed Blopress (candesartan cilexetil) and other available ARBs.
General manager of the company's pharmaceutical development division Dr Nancy Joseph-Ridge noted hypertension is one of the most prevalent, modifiable risk factors for cardiovascular disease.
"Tak-536 is positioned to become the successor of Blopress ? and we expect it will further enhance Takeda's cardiovascular franchise," she said.
"We will look forward to continuing the development of Tak-536 and to providing it as soon as possible to hypertensive patients ? in order to better control their blood pressure."
Last week, the business launched two new dose of Blopress Plus in Germany ? 25 mg and 12.5 mg.Other news stories from 25/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
